Cagrilintide (revision 2)
Old revision·21:16, 17 Aug 2024·COA_Colwyn
This is an old revision of this page, as it stood at 21:16, 17 Aug 2024, saved by COA_Colwyn with the summary give the INN alongside the trade name at first mention. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| Cagrilintide | |
|---|---|
| Class | Amylin receptor agonist |
| Route | Subcutaneous, weekly |
| Status | Investigational; not approved alone |
| Combination | CagriSema with semaglutide |
| Compound infobox · conventions | |
Cagrilintide is a long-acting analogue of amylin, engineered to resist the aggregation that makes the native human sequence undevelopable and acylated for albumin binding so that weekly dosing is possible.[1]
Its actions follow those of amylin: slowed gastric emptying, suppression of postprandial glucagon, and reduced food intake through hindbrain circuits distinct from the GLP-1 pathway.[2]
References
- ^ Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity." The Lancet 398(10317):2160–2172 (2021). PMID 34798060.
- ^ Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. "Amylin: pharmacology, physiology, and clinical potential." Pharmacological Reviews 67(3):564–600 (2015). PMID 26071095.
Categories: